[1] Kim J. Apelin-APJ signaling:a potential therapeutic target for pulmonary arterial hypertension[J]. Mol Cells, 2014, 37(3):196-201. [2] 范小芳, 王青, 毛孙忠, 等. 外源性apelin对大鼠慢性低氧性肺动脉高压的防治作用[J]. 中国应用生理学杂志, 2010, 26(1):9-12. [3] 范风云, 沈婉婷, 郑青青, 等. 低氧性肺动脉高压小鼠体内脂质水平的变化[J]. 中国应用生理学杂志, 2016, 32(5):463-465. [4] Than A, Cheng Y, Foh LC, et al. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways[J]. Mol Cell Endocrinol, 2012, 362(1-2):227-241. [5] Chandra SM, Razavi H, Kim J, et al. Disruption of the Apelin-APJ system worsens hypoxia-induced pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol, 2011, 31(4):814-820. [6] Lawrie A, Hameed AG, Chamberlain J, et al. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner[J]. Am J Pathol, 2011, 179(4):1693-1705. [7] Douglas RM, Bowden K, Pattison J, et al. Intermittent hypoxi a and hypercapnia induce pulmonary artery atherosclerosis and ventricular dysfunction in low dens ity lipoprotein receptor deficient mice[J]. J Appl Physiol (1985), 2013, 115(11):1694-1704. [8] Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events[J]. N Engl J Med, 2014, 371(25):2383-2393. [9] Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics[J]. Pharmacol Res, 2016, 111:76-85. [10] Alastalo TP, Li M, Perez Vde J, et al. Disruption of PPARγ/β-catenin-med iated regulation of apelin impairs BMP-induced mouse and human pulmonary arteri al EC survival[J]. J Clin Invest, 2011, 121(9):3735-3746. [11] Nisbet RE, Bland JM, Kleinhenz DJ, et al. Rosiglitazone atte nuates chronic hypoxia-induced pulmonary hypertension in a mouse model[J]. Am J Respir Ce ll Mol Biol, 2010, 42(4):482-490. |